Institutional shares held 160 Million
90K calls
14.2K puts
Total value of holdings $8.51B
$4.78M calls
$754K puts
Market Cap $2.08B
39,222,600 Shares Out.
Institutional ownership 408.26%
# of Institutions 628


Latest Institutional Activity in TECH

Top Purchases

Q2 2025
Kera Capital Partners, Inc. Shares Held: 5.37K ($285K)
Q2 2025
Rowland & CO Investment Counsel Shares Held: 40.5K ($2.15M)
Q2 2025
Central Pacific Bank Trust Division Shares Held: 3.64K ($193K)
Q1 2025
Select Equity Group, L.P. Shares Held: 5.37M ($285M)
Q1 2025
Wellington Management Group LLP Shares Held: 1.15M ($61M)

Top Sells

Q1 2025
Citadel Advisors LLC Shares Held: 460K ($24.4M)
Q1 2025
Ameriprise Financial Inc Shares Held: 3.59M ($191M)
Q1 2025
Janus Henderson Group PLC Shares Held: 18.1K ($960K)
Q1 2025
Bamco Inc Shares Held: 3.28M ($174M)
Q1 2025
Marshall Wace, LLP Shares Held: 877K ($46.6M)

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.


Insider Transactions at TECH

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
206K Shares
From 17 Insiders
Grant, award, or other acquisition 12.7K shares
Exercise of conversion of derivative security 193K shares
Sell / Disposition
120K Shares
From 9 Insiders
Payment of exercise price or tax liability 87.4K shares
Open market or private sale 32.5K shares

Track Institutional and Insider Activities on TECH

Follow BIO-TECHNE Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TECH shares.

Notify only if

Insider Trading

Get notified when an Bio Techne Corp insider buys or sells TECH shares.

Notify only if

News

Receive news related to BIO-TECHNE Corp

Track Activities on TECH